Research ExplorerPublicationsThe burden of systemic sclerosis in Switzerland - the Swiss ...

The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort

Standard

The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort. / Hernández, J; Jordan, S; Dobrota, R; Iudici, M; Hasler, P; Ribi, C; Villiger, P; Vlachoyiannopoulos, P; Vacca, A; Garzanova, L; Giollo, A; Rosato, E; Kötter, I; Carreira, Patricia E; Doria, Andrea; Henes, Jörg; Müller-Ladner, Ulf; Smith, Vanessa; Distler, Jörg H; Gabrielli, Armando; Hoffmann-Vold, Anna-Maria; Walker, Ulrich A; Distler, Oliver; EUSTAR Collaborators.

In: SWISS MED WKLY, Vol. 151, w20528, 05.07.2021, p. w20528.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hernández, J, Jordan, S, Dobrota, R, Iudici, M, Hasler, P, Ribi, C, Villiger, P, Vlachoyiannopoulos, P, Vacca, A, Garzanova, L, Giollo, A, Rosato, E, Kötter, I, Carreira, PE, Doria, A, Henes, J, Müller-Ladner, U, Smith, V, Distler, JH, Gabrielli, A, Hoffmann-Vold, A-M, Walker, UA, Distler, O & EUSTAR Collaborators 2021, 'The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort', SWISS MED WKLY, vol. 151, w20528, pp. w20528. https://doi.org/10.4414/smw.2021.20528

APA

Hernández, J., Jordan, S., Dobrota, R., Iudici, M., Hasler, P., Ribi, C., Villiger, P., Vlachoyiannopoulos, P., Vacca, A., Garzanova, L., Giollo, A., Rosato, E., Kötter, I., Carreira, P. E., Doria, A., Henes, J., Müller-Ladner, U., Smith, V., Distler, J. H., ... EUSTAR Collaborators (2021). The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort. SWISS MED WKLY, 151, w20528. [w20528]. https://doi.org/10.4414/smw.2021.20528

Vancouver

Hernández J, Jordan S, Dobrota R, Iudici M, Hasler P, Ribi C et al. The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort. SWISS MED WKLY. 2021 Jul 5;151:w20528. w20528. https://doi.org/10.4414/smw.2021.20528

Bibtex

@article{3d2a9fdbf9ab45158caf5cf0fd14ef2c,
title = "The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort",
abstract = "OBJECTIVES: Characteristics of Swiss patients with systemic sclerosis have not been described so far. The aim of the current study was to identify unmet needs in comparison with other European countries that could inform specific interventions to improve the care of systemic sclerosis patients.METHODS: We analysed Swiss and other European systemic sclerosis patients registered in European Scleroderma Trials And Research (EUSTAR) and the Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) cohort. Demographics, clinical profiles, organ involvement and survival of established, early/mild and very early / very mild systemic sclerosis patients were described and compared between the cohorts.RESULTS: We included 679 Swiss and 8793 European systemic sclerosis patients in the analysis. Over 95% of patients in both cohorts were Caucasian, disease subsets were similar, and no age difference was found. The Swiss cohort had more male patients (25% vs 16% European, p = 0.005) and higher prevalence of early/mild and very early / very mild patients (26.1 vs 8.5% European and 14.9% vs 6.7% European, respectively, both p <0.0001). Disease duration in established systemic sclerosis patients at first presentation was numerically shorter but not significant in the Swiss cohort: 5.0 years (1&ndash;12) Swiss vs 6.0 years (2&ndash;12) years European, p = 0.055). Despite the earlier referral of Swiss patients to systemic sclerosis expert centres, they showed evidence of more severe disease, particularly in the limited cutaneous systemic sclerosis subset, but no differences in overall survival on longitudinal follow-up were observed.CONCLUSION: This is the first report of the national Swiss EUSTAR cohort. It identifies earlier referral to systemic sclerosis expert centres, before major organ damage occurs, and when outcome can still be modified, as a priority to improve care of patients with systemic sclerosis.",
author = "J Hern{\'a}ndez and S Jordan and R Dobrota and M Iudici and P Hasler and C Ribi and P Villiger and P Vlachoyiannopoulos and A Vacca and L Garzanova and A Giollo and E Rosato and I K{\"o}tter and Carreira, {Patricia E} and Andrea Doria and J{\"o}rg Henes and Ulf M{\"u}ller-Ladner and Vanessa Smith and Distler, {J{\"o}rg H} and Armando Gabrielli and Anna-Maria Hoffmann-Vold and Walker, {Ulrich A} and Oliver Distler and {EUSTAR Collaborators}",
year = "2021",
month = jul,
day = "5",
doi = "10.4414/smw.2021.20528",
language = "English",
volume = "151",
pages = "w20528",
journal = "SWISS MED WKLY",
issn = "1424-7860",
publisher = "EMH Swiss Medical Publishers Ltd.",

}

RIS

TY - JOUR

T1 - The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort

AU - Hernández, J

AU - Jordan, S

AU - Dobrota, R

AU - Iudici, M

AU - Hasler, P

AU - Ribi, C

AU - Villiger, P

AU - Vlachoyiannopoulos, P

AU - Vacca, A

AU - Garzanova, L

AU - Giollo, A

AU - Rosato, E

AU - Kötter, I

AU - Carreira, Patricia E

AU - Doria, Andrea

AU - Henes, Jörg

AU - Müller-Ladner, Ulf

AU - Smith, Vanessa

AU - Distler, Jörg H

AU - Gabrielli, Armando

AU - Hoffmann-Vold, Anna-Maria

AU - Walker, Ulrich A

AU - Distler, Oliver

AU - EUSTAR Collaborators

PY - 2021/7/5

Y1 - 2021/7/5

N2 - OBJECTIVES: Characteristics of Swiss patients with systemic sclerosis have not been described so far. The aim of the current study was to identify unmet needs in comparison with other European countries that could inform specific interventions to improve the care of systemic sclerosis patients.METHODS: We analysed Swiss and other European systemic sclerosis patients registered in European Scleroderma Trials And Research (EUSTAR) and the Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) cohort. Demographics, clinical profiles, organ involvement and survival of established, early/mild and very early / very mild systemic sclerosis patients were described and compared between the cohorts.RESULTS: We included 679 Swiss and 8793 European systemic sclerosis patients in the analysis. Over 95% of patients in both cohorts were Caucasian, disease subsets were similar, and no age difference was found. The Swiss cohort had more male patients (25% vs 16% European, p = 0.005) and higher prevalence of early/mild and very early / very mild patients (26.1 vs 8.5% European and 14.9% vs 6.7% European, respectively, both p <0.0001). Disease duration in established systemic sclerosis patients at first presentation was numerically shorter but not significant in the Swiss cohort: 5.0 years (1&ndash;12) Swiss vs 6.0 years (2&ndash;12) years European, p = 0.055). Despite the earlier referral of Swiss patients to systemic sclerosis expert centres, they showed evidence of more severe disease, particularly in the limited cutaneous systemic sclerosis subset, but no differences in overall survival on longitudinal follow-up were observed.CONCLUSION: This is the first report of the national Swiss EUSTAR cohort. It identifies earlier referral to systemic sclerosis expert centres, before major organ damage occurs, and when outcome can still be modified, as a priority to improve care of patients with systemic sclerosis.

AB - OBJECTIVES: Characteristics of Swiss patients with systemic sclerosis have not been described so far. The aim of the current study was to identify unmet needs in comparison with other European countries that could inform specific interventions to improve the care of systemic sclerosis patients.METHODS: We analysed Swiss and other European systemic sclerosis patients registered in European Scleroderma Trials And Research (EUSTAR) and the Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) cohort. Demographics, clinical profiles, organ involvement and survival of established, early/mild and very early / very mild systemic sclerosis patients were described and compared between the cohorts.RESULTS: We included 679 Swiss and 8793 European systemic sclerosis patients in the analysis. Over 95% of patients in both cohorts were Caucasian, disease subsets were similar, and no age difference was found. The Swiss cohort had more male patients (25% vs 16% European, p = 0.005) and higher prevalence of early/mild and very early / very mild patients (26.1 vs 8.5% European and 14.9% vs 6.7% European, respectively, both p <0.0001). Disease duration in established systemic sclerosis patients at first presentation was numerically shorter but not significant in the Swiss cohort: 5.0 years (1&ndash;12) Swiss vs 6.0 years (2&ndash;12) years European, p = 0.055). Despite the earlier referral of Swiss patients to systemic sclerosis expert centres, they showed evidence of more severe disease, particularly in the limited cutaneous systemic sclerosis subset, but no differences in overall survival on longitudinal follow-up were observed.CONCLUSION: This is the first report of the national Swiss EUSTAR cohort. It identifies earlier referral to systemic sclerosis expert centres, before major organ damage occurs, and when outcome can still be modified, as a priority to improve care of patients with systemic sclerosis.

UR - http://europepmc.org/abstract/med/34283895

U2 - 10.4414/smw.2021.20528

DO - 10.4414/smw.2021.20528

M3 - SCORING: Journal article

C2 - 34283895

VL - 151

SP - w20528

JO - SWISS MED WKLY

JF - SWISS MED WKLY

SN - 1424-7860

M1 - w20528

ER -